The human malaria parasite, Plasmodium falciparum, is transmitted by a
mosquito vector, which consumes infected red blood cells from one
individual, and after sexual development and sporogony of the parasite,
injects infectious sporozoites into another individual. Not all blood
stage parasites are competent to develop in the mosquito. Asexual blood
stage parasites can only complete their life cycle in the human host,
giving rise to more parasites and the clinical symptoms of malaria.
Other blood stage parasites differentiate sexually into male and female
gametocytes that can continue developing only in the mosquito.
Expression of unique gametocyte stage genes is necessary for sexual
differentiation and successful mosquito transmission.
The long term objective of this research proposal is to produce a
physical map of the stage specific transcriptional activity along large
continuous stretches of DNA (tens to hundreds of kB) flanking two model
gametocyte stage genes, the pfs16 and pfg27/25 genes. These genes are
transcribed exclusively in the sexual stages. In laboratory isolates
which have lost the capacity to differentiate sexually and complete their
life cycle, the pfs16 and pfg27/25 genes are not transcribed. I propose
to isolate these genes on yeast artificial chromosomes (YACs) to test the
hypothesis that sexual stage genes are coordinately transcribed. Asexual
and gametocyte stage cDNA or RNA probes will identify and determine the
stage specificity of new blood stage transcription units on the YAC
clones around the model gametocyte stage genes. This unique approach may
identify new gametocyte stage antigens as potential targets for
transmission blocking immunity.
We have identified a mutant P. falciparum isolate in which the pfg27/25
gene is aberrantly transcribed in the asexual stages. Comparison of the
transcriptional environment around the gene in wild type asexual
parasites and in the mutant will determine whether inappropriate
activation of a gene modifies the transcriptional stage of nearby genes.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
041968306
UEI
NX9PXMKW5KW8
Project Start Date
01-December-1992
Project End Date
30-November-1997
Budget Start Date
01-December-1993
Budget End Date
30-November-1994
Project Funding Information for 1994
Total Funding
$108,388
Direct Costs
$64,709
Indirect Costs
$43,679
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Allergy and Infectious Diseases
$108,388
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R29AI033494-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R29AI033494-02
Patents
No Patents information available for 5R29AI033494-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R29AI033494-02
Clinical Studies
No Clinical Studies information available for 5R29AI033494-02
News and More
Related News Releases
No news release information available for 5R29AI033494-02
History
No Historical information available for 5R29AI033494-02
Similar Projects
No Similar Projects information available for 5R29AI033494-02